Medytox

Korea-based biopharmaceutical company Medytox has reportedly revamped its strategy for entering the Chinese market, according to Koreabiomed.com. After withdrawing a drug registration filing for its Meditoxin/Neuronox (Botulinum toxin type A; BTX) with the National Medical Products Administration (NMPA) in 2018, Medytox is now setting its sights on introducing Newlux, a…